PharmaCielo (TSE:PCLO)
:PCLO
Top Page
PharmaCielo
(PCLO)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.04
▲(10.00% Upside)
Action:ReiteratedDate:03/25/26
The score is held down primarily by weak financial performance—declining revenue, large ongoing losses, negative equity, and continued negative free cash flow—creating elevated solvency and funding risk. Technicals add a modest drag given the price is below key moving averages with subdued momentum, while a low P/E offers some valuation support but is outweighed by the fundamental risks.
Positive Factors
B2B standardized cannabinoid ingredient focus
A B2B focus on standardized cannabinoid ingredients creates durable, contractable revenue relationships with manufacturers and institutional buyers. Standardization supports regulatory compliance and repeat orders, enabling scale-driven efficiency and stickier customer demand over months.
Negative Factors
Declining revenue
A 16.6% TTM revenue decline erodes the base needed to cover fixed costs and reach scale. Persistent top-line contraction undermines margin recovery, increases per-unit overhead, and lengthens the time to profitability absent clear demand drivers or contract wins.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B standardized cannabinoid ingredient focus
A B2B focus on standardized cannabinoid ingredients creates durable, contractable revenue relationships with manufacturers and institutional buyers. Standardization supports regulatory compliance and repeat orders, enabling scale-driven efficiency and stickier customer demand over months.
Read all positive factors
PharmaCielo (PCLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.92M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)5.2
Beta (1Y)-2.58
Revenue Growth15.64%
EPS Growth58.47%
CountryCA
Employees268
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmaCielo Business Overview & Revenue Model
Company Description
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellne...
How the Company Makes Money
PharmaCielo makes money primarily through the sale of cannabis-derived products and ingredients. Its core revenue model is B2B: producing cannabinoid inputs (e.g., CBD-rich extracts/oils, distillates, isolates, or other standardized formulations) ...
PharmaCielo Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.61M | 3.48M | 1.54M | 5.31M | 1.94M |
| Gross Profit | 756.40K | 730.88K | -1.37M | 827.06K | -4.31M |
| EBITDA | -1.00M | -4.60M | -12.19M | -10.50M | -24.84M |
| Net Income | -4.55M | -9.14M | -16.30M | -16.04M | -26.92M |
Balance Sheet | |||||
| Total Assets | 8.56M | 18.39M | 22.29M | 25.12M | 35.96M |
| Cash, Cash Equivalents and Short-Term Investments | 289.24K | 147.94K | 62.18K | 325.98K | 5.63M |
| Total Debt | 18.65M | 20.52M | 18.31M | 12.59M | 8.43M |
| Total Liabilities | 23.92M | 25.91M | 23.97M | 18.72M | 16.63M |
| Stockholders Equity | -15.35M | -7.52M | -1.68M | 6.39M | 19.33M |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -1.97M | -5.17M | -10.23M | -21.21M |
| Operating Cash Flow | -1.02M | -1.97M | -5.15M | -9.71M | -20.07M |
| Investing Cash Flow | 6.66M | 41.14K | 391.64K | -725.49K | -1.66M |
| Financing Cash Flow | -5.52M | 2.02M | 4.63M | 5.30M | 18.21M |
PharmaCielo Technical Analysis
Negative
0.04
Price Trends
0.06
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
41.33
Neutral
20.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PCLO, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.33 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PCLO.
PharmaCielo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$8.44M | 8.94 | 11.57% | ― | -1.14% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$29.96M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
50 Neutral | C$59.88M | -2.97 | -19.76% | ― | 26.91% | 81.01% | |
49 Neutral | C$27.35M | -3.31 | -19.10% | ― | 18.06% | 34.58% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$6.92M | 5.19 | ― | ― | 15.64% | 58.47% |
* Healthcare Sector Average
TSE:PCLO
PharmaCielo
0.05
-0.04
-43.75%
TSE:ATLE
Willow Biosciences Inc
0.17
0.12
246.94%
TSE:LABS
MediPharm Labs
0.07
-0.02
-23.53%
TSE:OILS
Nextleaf Solutions
0.05
>-0.01
-16.67%
TSE:AVCN
Avicanna
0.15
-0.09
-37.50%
TSE:INNO
InnoCan Pharma
6.66
-4.72
-41.45%
PharmaCielo Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
PharmaCielo Pays Debenture Interest in Shares Ahead of April AGM
Neutral
Mar 17, 2026
PharmaCielo Ltd., the Canadian parent of Colombia-based cannabis cultivator and producer PharmaCielo Colombia Holdings S.A.S., has issued 12,153,937 common shares at an effective price of $0.08 to satisfy $972,317.12 in semi-annual interest owed o...
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
PharmaCielo Turns EBITDA Positive as It Refocuses on Higher-Margin Exports
Positive
Mar 2, 2026
PharmaCielo reported results for the quarter and nine months ended December 31, 2025, highlighting a swing to positive adjusted EBITDA of $293,000 from a loss of $2.3 million a year earlier, despite revenue declining to $1.8 million from $3.2 mill...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
PharmaCielo Sets AGM Date and Moves to Pay Debenture Interest in Shares
Neutral
Feb 17, 2026
PharmaCielo Ltd. has scheduled its annual general meeting of shareholders for April 2, 2026, with a record date of February 23, 2026 for investors entitled to receive notice and vote. Meeting materials will be made available to shareholders in lin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.